IRMD
IRadimed Corporation NASDAQ$84.92
Mkt Cap $1.1B
52w Low $50.31
60.1% of range
52w High $107.90
50d MA $96.51
200d MA $86.07
P/E (TTM)
49.2x
EV/EBITDA
41.6x
P/B
11.7x
Debt/Equity
0.0x
ROE
23.8%
P/FCF
72.0x
RSI (14)
—
ATR (14)
—
Beta
1.12
50d MA
$96.51
200d MA
$86.07
Avg Volume
84.0K
About
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also p…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | BMO | 0.46 | 0.49 | +6.5% | 83.44 | -2.7% | +4.4% | +1.8% | +0.7% | — | — | — |
| Feb 10, 2026 | BMO | 0.49 | 0.54 | +10.2% | 95.97 | +3.5% | +9.6% | +7.4% | +4.0% | +4.0% | +4.9% | — |
| Nov 3, 2025 | BMO | 0.48 | 0.47 | -2.1% | 76.81 | +7.1% | +9.5% | +12.9% | +10.6% | +10.2% | +9.8% | — |
| Aug 1, 2025 | BMO | 0.45 | 0.49 | +8.9% | 58.34 | +7.6% | +13.4% | +21.2% | +19.2% | +20.5% | +18.2% | — |
| May 5, 2025 | BMO | 0.43 | 0.42 | -2.3% | 53.47 | +0.8% | -2.2% | -4.6% | -4.6% | -1.5% | -3.0% | — |
| Feb 13, 2025 | BMO | 0.45 | 0.44 | -2.2% | 60.48 | -4.2% | -8.4% | -8.7% | -5.8% | -6.2% | -5.5% | — |
| Oct 31, 2024 | BMO | 0.39 | 0.43 | +10.3% | 52.94 | +2.0% | -6.9% | -8.8% | -6.8% | -0.4% | +6.2% | — |
| Aug 1, 2024 | BMO | 0.37 | 0.42 | +13.5% | 46.71 | +2.2% | -1.2% | -4.9% | -5.2% | -6.6% | -7.5% | — |
| May 2, 2024 | BMO | 0.34 | 0.36 | +5.9% | 42.00 | +1.4% | +4.4% | +6.4% | +3.8% | +4.0% | +3.4% | — |
| Feb 8, 2024 | BMO | 0.40 | 0.39 | -2.5% | 46.53 | -1.4% | +0.0% | -6.9% | -2.0% | -3.3% | -1.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14 | Roth MKM | Maintains | Buy → Buy | — | $55.41 | $55.40 | -0.0% | -0.3% | +2.8% | +2.4% | +3.1% | +1.5% |
| Aug 2 | Roth MKM | Maintains | Buy → Buy | — | $46.15 | $44.46 | -3.7% | -3.8% | -4.1% | -5.4% | -6.3% | -4.9% |
| Aug 2 | Roth Capital | Maintains | Buy → Buy | — | $33.66 | $34.02 | +1.1% | +3.4% | +1.0% | +0.6% | +7.1% | +7.9% |
| Jul 31 | Roth Capital | Upgrade | Neutral → Buy | — | $9.80 | $10.20 | +4.1% | +0.5% | -3.1% | -1.5% | -2.8% | -1.5% |
| Oct 5 | Roth Capital | Downgrade | Buy → Neutral | — | $10.77 | $10.77 | +0.0% | -0.3% | -2.4% | -4.2% | -4.5% | -5.3% |
| Apr 4 | Roth Capital | Maintains | Buy → Buy | — | $19.36 | $18.00 | -7.0% | -19.9% | -25.2% | -21.7% | -24.3% | -25.1% |
| Jun 16 | Roth Capital | Maintains | Buy → Buy | — | $20.60 | $20.80 | +1.0% | -0.9% | +0.5% | +3.9% | +8.5% | +9.0% |
Recent Filings
8-K
IRadimed Corporation -- 8-K Filing
IRadimed achieved 13% Q1 2026 revenue growth to $22.0 million, announced a $0.20 quarterly dividend, and delivered record diluted EPS of $0.45 while maintaining full-year guidance.
May 1
8-K
iRadimed Corporation -- 8-K Filing
iRadimed Corporation achieved record Q4 2025 revenue of $22.7 million with 17% year-over-year growth and raised its quarterly dividend to $0.20 per share, signaling strong profitability and management confidence.
Feb 10
Data updated apr 25, 2026 4:16pm
· Source: massive.com